Passage BIO, Inc.
PASG- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001787297
No open-market purchases or sales by Passage BIO, Inc. insiders were filed in the last 90 days; 29 institutions reported holding it in 13F filings for Q2 2026, worth $6.82M in total; no superinvestor holds it.
13F holders, Q2 2021
Institutional positions in Passage BIO, Inc. as of Jun 30, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 102
- +12 vs. Q1 2021
- Shares held
- 44.6M
- −400.8K (−0.9%) vs. Q1 2021
- Total value
- $558.8M
- −$227.7M (−28.9%) vs. Q1 2021
- New holders
- 21
- 43 more added
- Sold out
- 9
- 17 more reduced
Compare with Q1 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting PASG on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 29 | $6.82M |
| Q1 2026 | 35 | $13.8M |
| Q4 2025 | 30 | $18.6M |
| Q3 2025 | 32 | $13.2M |
| Q2 2025 | 41 | $13.0M |
| Q1 2025 | 42 | $12.8M |
| Q4 2024 | 46 | $21.6M |
| Q3 2024 | 45 | $27.1M |
| Q2 2024 | 45 | $32.0M |
| Q1 2024 | 51 | $54.4M |
| Q4 2023 | 52 | $33.1M |
| Q3 2023 | 51 | $21.3M |
| Q2 2023 | 56 | $31.4M |
| Q1 2023 | 59 | $34.0M |
| Q4 2022 | 68 | $51.6M |
| Q3 2022 | 76 | $49.3M |
| Q2 2022 | 87 | $99.6M |
| Q1 2022 | 110 | $133.2M |
| Q4 2021 | 102 | $277.7M |
| Q3 2021 | 103 | $419.1M |
| Q2 2021 | 102 | $558.8M |
| Q1 2021 | 90 | $786.5M |
Institutions, Q2 2021
Shares, value and share of portfolio for each institution holding Passage BIO, Inc.; share changes are against Q1 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| FMR LLC | 6,563,308 | $86.9M | 0.01% | −1,511,379−18.7% | Reduced |
| OrbiMed Advisors LLC | 6,962,899 | $92.2M | 0.94% | 00.0% | Unchanged |
| Royce & Associates LP | 0 | $0 | 0.00% | −84,000−100.0% | Sold out |
| Raymond James & Associates | 0 | $0 | 0.00% | −52,886−100.0% | Sold out |
| California Public Employees Retirement System | 0 | $0 | 0.00% | −50,736−100.0% | Sold out |
| Migdal Insurance & Financial Holdings Ltd. | 0 | $0 | 0.00% | −28,267−100.0% | Sold out |
| ExodusPoint Capital Management, LP | 0 | $0 | 0.00% | −13,956−100.0% | Sold out |
| Bank of Montreal | 0 | $0 | 0.00% | −8,739−100.0% | Sold out |
| Rockefeller Capital Management L.P. | 0 | $0 | 0.00% | −7,572−100.0% | Sold out |
| Pacer Advisors, Inc. | 0 | $0 | 0.00% | −2,120−100.0% | Sold out |
| Steward Partners Investment Advisory, LLC | 0 | $0 | 0.00% | −200−100.0% | Sold out |